Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients (original) (raw)

References

  1. De Angelis R, Capocaccia R, Verdecchia A. 1997 Estimating relative survival of Italian cancer patients from sparse cancer registries data.Tumori83:33–38
    PubMed Google Scholar
  2. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ. 2000 Prognostic factors in breast cancer. College of American Pathologist Consensus Statement 1999 Arch Pathol Lab Med 124:966–978
    PubMed CAS Google Scholar
  3. Isaacs C, Stearns V, Hayes DF. 2001 New prognostic factors for breast cancer recurrenceSemin Oncol 28:53–67
    Article PubMed CAS Google Scholar
  4. Clark GM, Sledge GW, Kent Osborne C, McGuire WL. 1987 Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patientsJ Clin Oncol 5:55–61
    PubMed CAS Google Scholar
  5. Miller AB, Hogestraeten B, Staquet M, Winkler A. 1981 Reporting results of cancer treatmentCancer 47:207–214
    Article PubMed CAS Google Scholar
  6. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MT, Gwyther SG. 2000 New guidelines to evaluate the response to treatment in solid tumorsJ Natl Cancer Inst 92:205–216
    Article PubMed CAS Google Scholar
  7. Pierga JY, Robain M, Jouve M, Asselain B, Dieras V, Beuzeboc P, Palangie T, Dorval T, Extra JM, Scholl S, Pouillart T. 2001 Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patientsAnn Oncol 12:231–237
    Article PubMed CAS Google Scholar
  8. Bruzzi P. 2002 Objective response to treatment as a potential surrogate marker of survival in breast cancerAnn NY Acad Sci 963:144–147
    Article PubMed Google Scholar
  9. Anderson JR, Cain KC, Gelber RD. 1983 Analysis of survival by tumor responseJ Clin Oncol 1:710–719
    PubMed CAS Google Scholar
  10. Del Mastro L, Sormani MP, Venturini M, Bastholt L, Bastit P, Brufman G, Focan C, Fountzilas G, Marschner N, Rosso R, Bruzzi P. 2002 Tumor response as surrogate end-point for survival in metastatic breast cancer patients: a meta-analysis [abstract]Ann Oncol 13(Suppl 3):15
    Google Scholar
  11. Stearns V, Yamauchi H, Hayes DF. 1998 Circulating tumor markers in breast cancer: accepted utilities and novel prospectsBreast Cancer Res Treat 52:239–259
    Article PubMed CAS Google Scholar
  12. Gion M, Cappelli G, Mione R, Pistorello M, Meo S, Vignati G, Fortunato A, Saracchini S, Biasioli R, Giulisano M. 1994 Evaluation of critical differences of CEA and CA 15-3 levels in serial samples from patients operated for breast cancerInt J Biol Markers 9:135–139
    PubMed CAS Google Scholar
  13. Tampellini M, Berruti A, Gerbino A, Buniva T, Torta M, Gorzegno G, Faggiuolo R, Cannone R, Farris A, Destefanis M, Moro G, Deltetto F, Dogliotti L. 1997 Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic diseaseBr J Cancer 75:698–702
    PubMed CAS Google Scholar
  14. Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe DW. 1988 Comparison of CA 15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancerCancer Res 48:4107–4112 Jul 15
    PubMed CAS Google Scholar
  15. Depres-Brummer P, Itzhaki M, Bakker PJ, Hoek FJ, Veenhof KH, de Wit R. 1995 The usefulness of CA 15-3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancerJ Cancer Res Clin Oncol 121:419–422
    Article PubMed CAS Google Scholar
  16. Soletormos G, Nielsen D, Schioler V, SkovsgaardT, Dombernowsky P. 1996 Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-upClin Chem 42:564–575
    PubMed CAS Google Scholar
  17. Sjostrom J, Alfthan H, Joensuu H, Stenman UH, Lundin J, Blomqvist C. 2001 Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancerScand J Clin Lab Invest 61:431–441
    Article PubMed CAS Google Scholar
  18. Einarsson R, Lindman H, Bergh J. 2000 Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patientsAnticancer Res 20:5089–5093
    PubMed CAS Google Scholar
  19. Cheung KL, Graves CR, Robertson JF. 2000 Tumour marker measurements in the diagnosis and monitoring of breast cancerCancer Treat Rev 26:91–102
    Article PubMed CAS Google Scholar
  20. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR. 2001 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical OncologyJ Clin Oncol 19:1865–1878
    PubMed Google Scholar
  21. Kallioniemi OP, Oksa H, Aaran RK, Hietanen T, Lehtinen N, Koivula T. 1988 Serum CA 15-3 assay in the diagnosis and follow-up of breast cancerBr J Cancer 58:213–215
    PubMed CAS Google Scholar
  22. Alabiso O, Durando A, Malossi A, Capello C, Martinotti R, Katsaros D, Genta F. 1998 A first-line therapy in metastatic breast cancer (MBC) with paclitaxel (T) and epidoxorubicin (E) regimen. A Phase I-II study [abstract]Tumori 84(Suppl 1):119
    Google Scholar
  23. Bumma C, Dogliotti L, Ciambellotti E, Botta M, Narcisi M, Gosso P, D’Arrigo A, Berruti A, Perroni D, Lauria G, Grecchi␣LG: 5-fluorouracil, epirubicin, cyclophosphamide (FEC) vs. epirubicin in advanced breast cancer. In: Proceedings of ECCO 5, 1989; London, September 3–7, 1989
  24. Dogliotti L, Berruti A, Buniva T, Zola P, Bau MG, Farris A, Sarobba MG, Bottini A, Tampellini M, Durando A, Destefanis M, Monzeglio C, Moro G, Sussio M, Perroni D. 1996 Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trialJ Clin Oncol 30:1165–1172
    Google Scholar
  25. Dogliotti L, Danese S, Berruti A, Zola P, Buniva T, Bottini A, Richiardi G, Moro G, Farris A, Bau MG, Porcile G. 1998 Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot studyCancer Chemother Pharmacol 41:333–338
    Article PubMed CAS Google Scholar
  26. Berruti A, Bitossi R, Gorzegno G, Bottini A, Durando A, De Matteis A, Nuzzo F, Giardina G, Danese S, De Lena M, Lorusso V, Farris A, Sarobba MG, DeFabiani E, Bonazzi G, Castiglione F, Bumma C, Moro G, Bruzzi P, Dogliotti L. 2002 Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addiction of either cisplatin or lonidamine: final results of a phase III study with a factorial designJ Clin Oncol 20:4150–4159
    Article PubMed CAS Google Scholar
  27. Harrell FE Jr., Lee KL, Califf RM, Pryor DB, Rosati RA. 1984 Regression modelling strategies for improved prognostic predictionStat Med 3:143–152
    Article PubMed Google Scholar
  28. Nie NH, Hull CH, Jeakins JG, Steinbrenner K, Bent Dh. 1988 Statistical package for the social sciences SPSS, Chicago
    Google Scholar
  29. Hortobagyi GN. 1998 Treatment of breast cancerN Engl J Med 339:974–984
    Article PubMed CAS Google Scholar
  30. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Busdar AU, Hortobagyi GN. 2001 Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyondThe Oncologist 6:133–146
    Article PubMed CAS Google Scholar
  31. Conte P, Gennari A, Landucci E, Guarneri V, Donati S, Salvadori B, Bengala C, Orlandini C. 2001 New combinations with epirubicin in advanced breast cancerOncology (Huntingt) 15(Suppl 7):24–27
    CAS Google Scholar
  32. Kiang DT, Greenberg LJ, Kennedy BJ. 1990 Tumor marker kinetics in the monitoring of breast cancerCancer 65:193–199
    Article PubMed CAS Google Scholar

Download references